Targeting HER2-positive cancer cells with receptor-redirected anthrax protective antigen

Therapeutic targets and recent advances in protein immunotoxins

(2012) Madhumathi J et al.   CURRENT OPINION IN MICROBIOLOGY

Changing the Receptor Specificity of Anthrax Toxin

(2012) A. Mechaly et al.   mBio

Treatment of HER2-positive breast cancer: current status and future perspectives

(2011) Carlos L. Arteaga et al.   Nature Reviews Clinical Oncology

Multiple molecular mechanisms underlying trastuzumab and lapatinib resistance in JIMT-1 breast cancer cells

(2010) Katri Köninki et al.   CANCER LETTERS

Affibody molecules: Engineered proteins for therapeutic, diagnostic and biotechnological applications

(2010) J. Löfblom et al.   FEBS LETTERS

The Protective Antigen Component of Anthrax Toxin Forms Functional Octameric Complexes

(2009) Alexander F. Kintzer et al.   JOURNAL OF MOLECULAR BIOLOGY

Membrane translocation by anthrax toxin

(2009) R. John Collier   MOLECULAR ASPECTS OF MEDICINE

HER2 in gastric cancer: a new prognostic factor and a novel therapeutic target

(2008) C. Gravalos et al.   ANNALS OF ONCOLOGY

Antibody-Drug Conjugates for Cancer Therapy

(2008) Paul J. Carter et al.   CANCER JOURNAL

Targeting HER2-Positive Breast Cancer with Trastuzumab-DM1, an Antibody-Cytotoxic Drug Conjugate

(2008) G. D. Lewis Phillips et al.   CANCER RESEARCH